MedTrace Logo

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

NCT04306965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses.

Conditions

Interventions

DRUG

Apremilast

30 mg twice daily (BID)

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • David Rosmarin, MD · Tufts Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-06-23
Completion
2022-08-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306965 on ClinicalTrials.gov